Cellectis’ (CLLS) Market Perform Rating Reiterated at Citizens Jmp

Citizens Jmp reissued their market perform rating on shares of Cellectis (NASDAQ:CLLS) in a research report released on Tuesday morning, MarketBeat reports.

A number of other brokerages have also recently weighed in on CLLS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellectis in a research report on Friday, July 17th. Barclays began coverage on Cellectis in a report on Thursday, May 28th. They set an “overweight” rating and a $9.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Cellectis presently has a consensus rating of “Hold” and a consensus price target of $5.46.

Cellectis Trading Up 6.2%

CLLS stock opened at $1.46 on Tuesday. Cellectis has a 1-year low of $1.25 and a 1-year high of $5.48. The firm has a market cap of $146.50 million, a P/E ratio of -2.25 and a beta of 2.92. The business’s 50 day moving average is $2.90 and its 200-day moving average is $3.28. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.61.

Cellectis (NASDAQ:CLLS) last issued its earnings results on Friday, August 7th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.04. The business had revenue of $6.90 million during the quarter, compared to analysts’ expectations of $11.05 million. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.

Institutional Trading of Cellectis

An institutional investor recently bought a new stake in Cellectis stock. Lido Advisors LLC purchased a new stake in Cellectis S.A. (NASDAQ:CLLS) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 10,094 shares of the biotechnology company’s stock, valued at approximately $32,000. Institutional investors and hedge funds own 63.90% of the company’s stock.

Key Headlines Impacting Cellectis

Here are the key news stories impacting Cellectis this week:

• Positive Sentiment: Cellectis plans to prioritize two preclinical in vivo gene-editing programs, a strategy that could provide a more focused path toward genetic medicines and potentially reduce internal development costs. The company is also seeking partners to continue development of the discontinued CAR-T programs. Cellectis Exits Two CAR-T Programs
• Neutral Sentiment: An analysis characterized the pivot as an “all or nothing” transition that warrants monitoring. The opportunity depends on whether Cellectis can demonstrate meaningful progress with its early-stage in vivo gene-editing platform. Cellectis In Vivo Gene-Editing Analysis
• Neutral Sentiment: Citizens JMP reiterated a Market Perform rating, indicating limited conviction that the strategic transformation will drive near-term outperformance. Citizens JMP Market Perform Rating
• Negative Sentiment: Analysts lowered their expectations for Cellectis. Wells Fargo reduced its price target to $3.00, while Robert W. Baird also lowered its expectations following the pipeline pivot. These actions reflect weaker near-term visibility after the company abandoned internal development of two CAR-T candidates. Wells Fargo Lowers Cellectis Price Target Baird Lowers Cellectis Expectations
• Negative Sentiment: Several law firms announced investigations into whether Cellectis complied with federal securities laws in connection with disclosures surrounding the strategic transformation. These announcements add potential legal and reputational overhang, although they do not establish wrongdoing. Holzer and Holzer Cellectis Investigation Frank R. Cruz Cellectis Investigation

About Cellectis

Cellectis SA (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis’ product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.